Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 9,463 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 9,463 shares of the stock in a transaction on Monday, April 20th. The stock was sold at an average price of $30.00, for a total value of $283,890.00. Following the transaction, the insider directly owned 299,368 shares in the company, valued at $8,981,040. The trade was a 3.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, March 17th, Soleil Boughton sold 4,812 shares of Hims & Hers Health stock. The stock was sold at an average price of $24.69, for a total value of $118,808.28.

Hims & Hers Health Price Performance

HIMS opened at $28.95 on Thursday. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The business’s fifty day simple moving average is $20.45 and its 200-day simple moving average is $31.74. The company has a market capitalization of $6.60 billion, a price-to-earnings ratio of 56.77, a PEG ratio of 2.83 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The business had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. During the same quarter in the prior year, the company earned $0.11 EPS. The business’s revenue was up 28.4% compared to the same quarter last year. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors have recently added to or reduced their stakes in the business. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in Hims & Hers Health by 0.8% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock worth $1,452,000 after acquiring an additional 200 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Hims & Hers Health by 6.1% in the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock worth $232,000 after acquiring an additional 236 shares in the last quarter. Concurrent Investment Advisors LLC boosted its holdings in Hims & Hers Health by 1.8% in the third quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after acquiring an additional 252 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in Hims & Hers Health by 44.7% in the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after acquiring an additional 283 shares in the last quarter. Finally, W.G. Shaheen & Associates DBA Whitney & Co boosted its holdings in Hims & Hers Health by 4.8% in the third quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company’s stock worth $436,000 after acquiring an additional 350 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HIMS. Truist Financial reaffirmed a “hold” rating and set a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research report on Friday, March 27th. Deutsche Bank Aktiengesellschaft raised their price objective on Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a research report on Tuesday, March 10th. Evercore set a $24.00 price objective on Hims & Hers Health in a research report on Tuesday, February 24th. Finally, Barclays raised their price target on Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 11th. Three equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $31.86.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Pipeline & partner speculation — Momentum behind HIMS has been driven by reports of FDA peptide news and a potential partnership with Novo Nordisk, which traders say helped push the stock higher as investors price in new commercial opportunities. Read More.
• Positive Sentiment: Product expansion — HIMS announced it will offer perimenopause/menopause treatment options (including estrogen patch access) on its telehealth platform, expanding addressable market and recurring-care use cases. This is a direct revenue opportunity and supports the company’s DTC care‑platform narrative. Read More.
• Neutral Sentiment: Sector/flow dynamics — Broader small‑cap biotech and telehealth sector enthusiasm (positive clinical results at peers, flow into health names) has amplified HIMS moves even where company‑specific catalysts are limited. That can accelerate swings up or down ahead of earnings. Read More.
• Neutral Sentiment: Analyst & institutional backdrop — Coverage is mixed: consensus is a “Hold” with a mid‑$30s/low‑$20s range of targets and heavy institutional ownership (~63%). Upgrades/target changes have helped sentiment but don’t fully resolve execution risk.
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe and other insiders have sold sizable blocks recently under pre‑arranged Rule 10b5‑1 plans (April filings). While 10b5‑1 execution mutes signaling, the volume and timing can weigh on near‑term sentiment. Read More. Read More.
• Negative Sentiment: Competitive threat — Amazon’s launch of a GLP‑1 weight‑loss program highlights new, deep-pocketed competition in a key monetizable category for HIMS (weight‑loss/medication access + ongoing care). That announcement pressured the stock amid concerns about margin compression and customer share loss. Read More.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.